Kalbe Farma Tbk PT
IDX:KLBF
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 015
1 600
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| ID |
|
Kalbe Farma Tbk PT
IDX:KLBF
|
55.5T IDR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
528.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
220.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
271.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
148.1B USD |
Loading...
|
Market Distribution
| Min | -111 644.7% |
| 30th Percentile | 0% |
| Median | 6.1% |
| 70th Percentile | 12.9% |
| Max | 524 864.9% |
Other Profitability Ratios
Kalbe Farma Tbk PT
Glance View
Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Kalbe Farma Tbk PT is 12.6%, which is below its 3-year median of 12.9%.
Over the last 3 years, Kalbe Farma Tbk PT’s Operating Margin has decreased from 15% to 12.6%. During this period, it reached a low of 11.9% on Dec 31, 2023 and a high of 15% on Sep 30, 2022.